<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rifamycins (rifampin, rifabutin, rifapentine)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rifamycins (rifampin, rifabutin, rifapentine)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Rifamycins (rifampin, rifabutin, rifapentine)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Drew, PharmD, MS, FCCP, FIDP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Bernardo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The rifamycins include <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a>, and <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>. Of these, rifampin is most commonly used, either as first-line therapy (in combination with other agents) for treatment of mycobacterial disease (including tuberculosis) or for select invasive staphylococcal infections (as part of combination therapy) [<a href="#rid1">1-4</a>].</p><p>Rifamycins (most notably <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>) are moderate to potent inducers of drugs undergoing metabolism by the cytochrome P450 enzyme system (notably CYP3A4), which can lead to reduced bioavailability and enhanced clearance of some coadministered medications. Such interactions may be delayed in onset but persist beyond rifamycin coadministration. Rifampin may also induce P-glycoprotein (P-gp) multidrug efflux transporters. Therefore, patients receiving any rifamycin should have their medication regimen analyzed carefully for drug interactions. This may be done by use of the <a class="external" href="/drug-interactions">drug interaction program</a> included within UpToDate.</p><p>Issues related to pharmacology of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>, and <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a> will be reviewed here. Issues related to clinical use of rifampin and rifapentine are discussed separately. (See related topics.)</p><p class="headingAnchor" id="H2"><span class="h1">RIFAMPIN</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> is the most commonly used rifamycin for treatment of nontuberculous mycobacterial (NTM) diseases, in combination with other agents [<a href="#rid2">2,5</a>]. It is also used for treatment of tuberculosis (active disease and latent infection), for prophylaxis following exposure to <em>Neisseria meningitidis</em> or <em>Haemophilus influenzae,</em> and as an adjunctive agent for treatment of select deep-seated staphylococcal infections. (See related topics.)</p><p class="headingAnchor" id="H3"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> is thought to inhibit bacterial DNA-dependent RNA polymerase, which appears to occur as a result of drug binding in the polymerase subunit deep within the DNA/RNA channel, facilitating direct blocking of the elongating RNA [<a href="#rid6">6</a>]. This effect is thought to be concentration related [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Resistance</span><span class="headingEndMark"> — </span>Resistance to <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> arises due to missense mutations in the <em>rpoB</em> gene and occurs in a variety of bacteria including <em>Mycobacterium tuberculosis</em>, <em>Staphylococcus aureus</em> (including methicillin-resistant <em>S. aureus</em> [MRSA]), <em>Streptococcus pneumoniae</em>, and Rickettsiae [<a href="#rid8">8-12</a>].</p><p>Phenotypic (culture-based) cross-resistance between <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and the other rifamycins (<a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> and <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a>) depends on the mutation type; it is extensive but not complete [<a href="#rid13">13,14</a>]. Molecular drug susceptibility testing (specifically nucleic acid amplification testing [NAAT]) is providing new insights into the potential significance of these mutations in the clinical management of tuberculosis. Since cross-resistance to other rifamycins is incomplete, it may be appropriate (in select cases, notably in patients with multidrug-resistant strains of <em>M. tuberculosis</em>) to perform rifabutin susceptibility testing when rifampin resistance is observed [<a href="#rid15">15</a>].</p><p>The rate of spontaneous resistance of <em>M. tuberculosis</em> via single-step mutation to <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> is 1 in 10<sup>8</sup> bacilli [<a href="#rid16">16</a>]. The rate of resistance in other types of bacteria (eg, <em>Escherichia coli</em>, <em>S. aureus</em>, <em>Streptococcus </em>spp, and <em>N. meningitidis</em>) is much higher [<a href="#rid17">17</a>]. Since the rate of development of resistance is both high and predictable, rifampin should be used as monotherapy only for prophylaxis against <em>N. meningitidis</em> or <em>H. influenzae</em>, or for latent infection with tuberculosis where the organism burden is relatively low.</p><p class="headingAnchor" id="H5"><span class="h2">Spectrum of in vitro activity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> is useful for treatment of intracellular pathogens due to high intracellular penetration. It demonstrates bactericidal activity in vitro against most strains of tuberculosis. Rifampin also demonstrates activity in vitro against NTM, including <em>Mycobacterium kansasii</em>. Activity against <em>Mycobacterium avium</em> complex (MAC) organisms is variable. (See  <a class="medical medical_review" href="/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults"</a>.)</p><p><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> demonstrates in vitro activity against a broad spectrum of bacteria other than <em>Mycobacteria</em> spp. Susceptible gram-positive organisms include <em>S. aureus</em>, coagulase-negative staphylococci, <em>Streptococcus pyogenes</em>, <em>Streptococcus pneumoniae</em>, viridans streptococci, and <em>Listeria monocytogenes</em>. Rifampin also has activity against <em>Chlamydia</em> spp and diverse gram-negative pathogens, including <em>Legionella</em> spp, <em>Brucella </em>spp, <em>H. influenzae</em>, <em>Haemophilus ducreyi</em>, <em>Neisseria gonorrhoeae</em>, and <em>N. meningitidis</em>.</p><p class="headingAnchor" id="H6"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> undergoes rapid and complete absorption after oral administration. Absorption may be formulation dependent and is improved when the oral dose is taken on an empty stomach but may be delayed or reduced if taken with food and in patients with diabetes and/or HIV infection [<a href="#rid18">18-21</a>]. Oral doses exceeding 10 mg/kg may result in a disproportionately high increase in dose-exposure relationship [<a href="#rid22">22,23</a>]. Rifampin undergoes wide distribution into most body tissues and fluids, including penetration into the cerebrospinal fluid (in patients with inflamed meninges). It concentrates intracellularly up to five times that of extracellular concentrations, primarily in polymorphonuclear leukocytes [<a href="#rid24">24</a>]. The protein binding of rifampin is approximately 80 percent.</p><p><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> undergoes extensive hepatic metabolism to less active metabolites, with a half-life of three hours. After multiple doses, exposure may decline after steady state is achieved, which may be due (at least in part) to autoinduction leading to enhanced clearance [<a href="#rid22">22,23,25</a>]. </p><p>Renal elimination of unchanged drug is minimal (&lt;30 percent). Caution should be exercised when <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> is administered to patients with significant hepatic disease, especially when used in combination with other hepatotoxins (such as <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>). (See  <a class="medical medical_review" href="/d/html/477.html" rel="external">"Isoniazid hepatotoxicity"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Dosing and administration</span><span class="headingEndMark"> — </span>The usual adult dose of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> for treatment of tuberculosis is 10 mg/kg (maximum 600 mg daily) given daily or (if given by directly observed therapy) two or three times weekly. Intravenous doses are similar to those administered orally. The usual pediatric dose range is 10 to 20 mg/kg per day, (up to a maximum of 600 mg) given daily by directly observed therapy [<a href="#rid3">3</a>]. Oral doses should be administered one hour before or two hours after meals. </p><p>Based on pharmacokinetic/pharmacodynamic studies (noting concentration-dependent activity and the variability in kinetic parameters), there is interest in use of higher <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> doses than those routinely recommended for tuberculosis treatment [<a href="#rid7">7,22,23,26-29</a>]. However, thus far, these higher doses of rifampin have not been associated with improved clinical response rates. In addition, dose intensification requires serum concentration monitoring.</p><p>Recommended doses of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> for adults with prosthetic valve endocarditis due to <em>S. aureus </em>are up to 300 mg every eight hours [<a href="#rid30">30</a>]. This may be administered for ≥6 weeks, in combination with other antistaphylococcal therapy. Reports of rifampin treatment for other invasive staphylococcal infections (such as osteomyelitis, prosthetic joint infections, and meningitis) generally utilize 600 to 900 mg per day (usually in two divided doses). (See  <a class="medical medical_review" href="/d/html/2141.html" rel="external">"Antimicrobial therapy of prosthetic valve endocarditis"</a>.)</p><p>No dose adjustments are needed for <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> in patients with renal dysfunction or those undergoing dialysis. </p><p><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> metabolism may be altered in patients with hepatic impairment. Caution should be exercised in administering rifampin to patients with underlying hepatic dysfunction; no formal guidelines are available to guide dosing in this population. </p><p class="headingAnchor" id="H2709752758"><span class="h2">Special populations</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> has been safely administered during pregnancy. Teratogenicity has been demonstrated in laboratory animals; therefore, it should be used only if potential benefits outweigh risks. Concentrations of rifampin in breast milk are reported to be insufficient to produce toxicity in the nursing newborn. Rifampin can cause orange discoloration to breast milk, which is considered harmless [<a href="#rid31">31</a>]. </p><p class="headingAnchor" id="H9"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Patients should be advised that <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> typically causes an orange or red-orange discoloration of body fluids (including urine, sweat, saliva, and tears).</p><p>Adverse effects associated with the administration of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> include gastrointestinal effects (nausea, vomiting, diarrhea), central nervous system effects (headache, fever), dermatologic effects (rash, itching, flushing), hematologic effects (thrombocytopenia, neutropenia, and acute hemolytic anemia), and pulmonary toxicity [<a href="#rid32">32</a>]. Pruritus (with or without rash) can occur but may not represent a true hypersensitivity reaction; therefore, continued use may be possible in some patients.</p><p>Hepatitis is infrequently associated with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> but is more commonly observed in patients with predisposing factors, including administration of concomitant hepatotoxins (such as <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>), HIV coinfection, history of liver disease, regular alcohol consumption, pregnancy, or postpartum patients. For unclear reasons, a high incidence of hepatotoxicity has been observed in patients treated with a two-month regimen of rifampin and <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a> for latent tuberculosis infection [<a href="#rid33">33</a>]. For this reason, subsequent guidelines have advised against use of this regimen.</p><p><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> can cause a flu-like syndrome beginning one to two hours after administration and resolving six to eight hours later [<a href="#rid34">34</a>]. Typically, this syndrome occurs more commonly with intermittent rather than daily therapy, particularly at higher doses. Most patients are able to tolerate rifampin if the interval is changed from intermittent to daily.</p><p>Reactions associated with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> that should prompt discontinuation of the drug include anaphylaxis, cutaneous vasculitis, red cell aplasia, leukopenia and agranulocytosis, thrombocytopenia, disseminated intravascular coagulation, hemolytic anemia, pulmonary infiltrates, lupoid reactions, and acute renal failure.</p><p class="headingAnchor" id="H10"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>All patients must be educated about possible symptoms of hepatic toxicity, including unexplained anorexia, nausea, vomiting, dark urine, icterus, rash, pruritus, persistent fatigue, weakness or fever lasting three or more days, abdominal discomfort (particularly right upper quadrant discomfort), or easy bruising or bleeding. Arthralgias also can occur. Patients should be directly questioned at visits for these symptoms. In addition, they should immediately report any signs or symptoms that occur between visits and stop the medication treatment pending further evaluation. All patients with such complaints should be fully evaluated clinically, including serum testing for hepatic injury.</p><p>The therapeutic serum concentration for <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> against <em>M. tuberculosis </em>is a two-hour post-dose concentration of 8 to 24 microgram/mL. (See  <a class="medical medical_review" href="/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a>.)  </p><p>Issues related to laboratory monitoring for patients on antituberculous drugs are discussed separately. (See  <a class="medical medical_review" href="/d/html/488.html" rel="external">"Antituberculous drugs: An overview", section on 'Clinical and laboratory monitoring'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> is a potent inducer of several drug-metabolizing enzymes as well as P-glycoprotein (P-gp) multidrug efflux transporters, which can lead to significant reductions in concentrations and therapeutic failure of other drugs. Drug interactions result from the ability of rifampin to induce cytochrome P450 CYP3A metabolism (and to a lesser extent CYP2C) and glucuronidation, thereby accelerating drug excretion. Rifampin also increases intestinal P-gp mediated drug efflux, thereby reducing gastrointestinal absorption of drugs that are P-gp substrates [<a href="#rid35">35-38</a>]. Such interactions include (but are not limited to) oral or other hormonal contraceptives, glucocorticoids, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, HMG-CoA reductase inhibitors ("statins"), macrolide antibiotics, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, direct oral anticoagulants (eg, <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>), <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a>, azole antifungal agents, oral sulfonylurea hypoglycemics, several antimalarials, <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, and beta-blockers.</p><p>There are a number of drug interactions between <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and antiretrovirals including integrase inhibitors (bictegravir, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, elvitegravir-containing formulations), protease inhibitors (lopinavir, <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> or <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> with or without <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a> or <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>), non-nucleoside reverse-transcriptase inhibitors (<a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a> and <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>), and <a class="drug drug_general" data-topicid="128916" href="/d/drug information/128916.html" rel="external">fostemsavir</a>. Use of rifampin with protease inhibitors is contraindicated [<a href="#rid39">39</a>]. </p><p>Information regarding the interactions between <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (as a treatment for tuberculosis) and antiretrovirals is dynamic. The United States Centers for Disease Control and Prevention maintains <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines%2Fhiv-clinical-guidelines-adult-and-adolescent-arv%2Foverview%3Fview%3Dfull&amp;token=lIaO8my2efZahcZ%2BWlFkcYfJsmvz9OI7OTXQbsNcmhXxWd1GcVR1MKig6y0KcROIQdfxE%2Bm1pHgw841say6yOGIq0GxLeS7miQ13OFlwpCCDbYym56j1MCbxtlee2sqB&amp;TOPIC_ID=491" target="_blank">guidelines</a> for management of such interactions [<a href="#rid3">3</a>]. Details about specific interactions may be obtained by using the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate.</p><p>While the onset of effect of enzyme induction (resulting in reductions in coadministered medication[s]) can be observed within hours following oral administration of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, the full effect can require up to two weeks. After rifampin discontinuation, the effect can persist while slowly abating over two weeks [<a href="#rid40">40-43</a>]. As a result of such interaction, substantial increase in dosage of the coadministered drug may be needed when taken either concomitant or immediately following rifampin administration. In clinical scenarios where serum concentration monitoring is available for the interacting drug (eg, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) more frequent measurements are needed when starting or stopping rifampin.</p><p class="headingAnchor" id="H1657985256"><span class="h1">RIFABUTIN</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">Rifabutin</a> has reduced potential for drug interactions (relative to <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>) [<a href="#rid44">44</a>]. Therefore, it is most commonly used for treatment of select mycobacterial infections in patients receiving concomitant medications exhibiting significant interactions with rifampin (such as select antiretroviral therapies) [<a href="#rid45">45</a>]. Rifabutin is approved by the US Food and Drug Administration for the prevention of disseminated <em>M. avium</em> complex (MAC) disease in patients with advanced HIV infection [<a href="#rid46">46</a>]. [<a href="#rid47">47,48</a>]</p><p class="headingAnchor" id="H1657985262"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">Rifabutin</a> inhibits DNA-dependent RNA polymerase at the beta subunit, thus preventing chain initiation [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H1657985268"><span class="h2">Resistance</span><span class="headingEndMark"> — </span>Rifampin-resistant isolates generally have been considered resistant to all rifamycins (including <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>). However, phenotypic cross-resistance is not universal [<a href="#rid13">13,14</a>]. In some studies, about 20 to 30 percent of rifampin-resistant multidrug-resistant tuberculosis strains demonstrate in vitro susceptibility to rifabutin [<a href="#rid49">49</a>]. It has been suggested that rifabutin susceptibility testing should be done in select cases when <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> resistance is observed [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H1657985274"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Following a single 300 mg oral dose, mean (±standard deviation) peak plasma <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> concentrations of 375 (±267) ng/mL have been reported [<a href="#rid46">46</a>]. In a healthy volunteer study, absolute oral bioavailability is approximately 20 percent, with the capsules achieving approximately 85 percent of the oral solution [<a href="#rid46">46</a>]. High-fat meals slow the rate (but not the extent) of absorption from the capsule dosage form. Rifabutin has extensive distribution and intracellular uptake. About 85 percent of the drug is bound to plasma proteins. Approximately 53 percent and 30 percent of the oral dose is excreted in the urine (primarily as metabolites) and stool, respectively. Less than 10 percent is excreted in urine as unchanged drug. A mean terminal half-life of 45 (±17) hours was reported in healthy volunteers.</p><p class="headingAnchor" id="H1657985280"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>For treatment of adults with tuberculosis, dosing of <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> is 5 mg/kg (max 300 mg) daily. For treatment of MAC in adults with HIV, dosing consists of 300 mg/day [<a href="#rid46">46,50</a>].</p><p><a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">Rifabutin</a> serum concentrations can be impacted by coadministration of agents that inhibit or induce CYA-3A4. In patients with HIV infection, coadministration of protease inhibitors (specifically <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> with or without booster [<a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>], <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> and lopinavir with or without booster [<a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>]) can significantly increase the area under the time-concentration curve for rifabutin. In such situations, rifabutin dosing for the treatment of tuberculosis should be reduced to 150 mg daily [<a href="#rid51">51</a>]. Subsequent rifabutin dose increases would be necessary if the interacting drugs were discontinued. In contrast, <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> coadministration may significantly reduce concentrations of rifabutin (see <a class="local">'Drug interactions'</a> below). Rifabutin should not be used with <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>/cobicistat or bictegravir.</p><p>In patients with significant renal impairment (creatinine clearance [CrCl] of &lt;30 ml/min), the manufacturer’s labeling recommends consideration of 50 percent dose reduction if toxicity is suspected. However, area under the curve values reported in patients with CrCl &lt;30 have been similar to those found in healthy volunteers, suggesting that no dose reduction is needed [<a href="#rid52">52,53</a>]. If available, therapeutic drug monitoring in these patients may be helpful, particularly if drug toxicity is suspected. </p><p class="headingAnchor" id="H1657985286"><span class="h2">Special populations</span><span class="headingEndMark"> — </span>Limited data are available for the use of <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> in children with tuberculosis and the appropriate dose is unknown. In such settings, 5 mg/kg mg/kg (maximum dose 300 mg) may be administered once daily [<a href="#rid3">3</a>]. </p><p><a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">Rifabutin</a> should not be administered as MAC prophylaxis to patients with active tuberculosis.</p><p class="headingAnchor" id="H1657985292"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Similar to other rifamycins, hematologic toxicity (most notably neutropenia) and hepatotoxicity have been reported in patients receiving <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>. Similar to <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, the risks of hepatotoxicity would be greatest in patients with predisposing factors, including administration of concomitant hepatotoxins (such as <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>), HIV coinfection, history of liver disease, regular alcohol consumption, pregnancy, or postpartum patients.</p><p>Rifabutin-induced uveitis has also been reported [<a href="#rid54">54</a>]. It is generally considered a rare, dose-related event. Concomitant administration of drugs that may increase serum concentrations of <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> (notably <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> or <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>) significantly increase the risk of this reaction.</p><p>Similar to other rifamycins, <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> administration may result in orange or red-orange discoloration of body fluids (including urine, sweat, saliva, and tears).</p><p>There have been reports of severe cutaneous adverse reactions due to <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>; these include Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis. </p><p class="headingAnchor" id="H1657985298"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Routine monitoring of <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> serum concentrations is not performed. Therapeutic concentration monitoring could assist in minimizing the risk of rifabutin-related toxicities, especially in the setting of coadministration of interacting agents (such as protease inhibitors).</p><p class="headingAnchor" id="H1657985304"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">Rifabutin</a> shares the property of uridine diphosphate gluconyltransferase 1A1 and CYP enzyme induction with other rifamycins (predominately CYP-3A4) but is generally considered less potent. However, significant interactions with rifabutin and CYP substrates do occur. As an example, coadministration of rifabutin (300 mg/day) and <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> (500 mg every 12 hours) decreased the area under the curve of clarithromycin by about 50 percent [<a href="#rid46">46</a>]. Trough <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> concentrations are reduced by coadministration with rifabutin by about 20 percent, although standard-dose raltegravir (400 mg twice daily) is recommended with concomitant rifabutin. In contrast, coadministration of <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a> (with or without <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>) with rifabutin is not recommended due to reductions of elvitegravir trough concentrations (67 percent) when cobicistat-boosted elvitegravir is given together with rifabutin [<a href="#rid55">55</a>].</p><p>Because <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> is also a substrate of CYP-3A4, its concentrations may be impacted by concomitant administration of agents inhibiting or inducing this enzyme. Protease inhibitors such as <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> (a potent CYP-3A4 inhibitor) may increase rifabutin serum concentrations by up to fourfold and its major metabolite by up to 35-fold [<a href="#rid55">55</a>]. Other protease inhibitors (such as <a class="drug drug_general" data-topicid="9685" href="/d/drug information/9685.html" rel="external">nelfinavir</a> and amprenavir) are also known to significantly increase rifabutin concentrations and often require dose reductions of rifabutin (see <a class="local">'Dosing'</a> above).</p><p>Coadministration of CYP-3A4 inducers may decrease serum concentrations of <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>. As an example, <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> (a potent CYP-3A4 inducer) decreases rifabutin serum concentrations by one-third. Therefore, the CDC recommends that <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> be used as the rifamycin of choice for patients taking efavirenz-based antiretroviral therapy [<a href="#rid55">55</a>].</p><p>Two-way interactions are also observed with agents coadministered with <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>. As an example, administration of rifabutin with <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a> may reduce etravirine concentrations while increasing rifabutin concentrations (35 percent and 17 percent, respectively) [<a href="#rid56">56</a>]; however, the CDC does not recommend dosing modifications in such situations [<a href="#rid55">55</a>].</p><p>Information regarding the interactions between protease inhibitors, <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> (as a treatment for tuberculosis), and antiretrovirals is dynamic. The CDC maintains <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines%2Fhiv-clinical-guidelines-adult-and-adolescent-arv%2Foverview%3Fview%3Dfull&amp;token=lIaO8my2efZahcZ%2BWlFkcYfJsmvz9OI7OTXQbsNcmhXxWd1GcVR1MKig6y0KcROIQdfxE%2Bm1pHgw841say6yOGIq0GxLeS7miQ13OFlwpCCDbYym56j1MCbxtlee2sqB&amp;TOPIC_ID=491" target="_blank">guidelines</a> as to the management of such interactions [<a href="#rid3">3</a>].</p><p>Specific interactions of <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> with other medications may be determined by using the <a class="external" href="/drug-interactions">drug interaction program</a> included within UpToDate. </p><p class="headingAnchor" id="H12"><span class="h1">RIFAPENTINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">Rifapentine</a> has a longer half-life than <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> [<a href="#rid57">57</a>]. </p><p><a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">Rifapentine</a> (administered in combination with <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, once weekly for three months) an accepted regimen for the treatment of latent tuberculosis [<a href="#rid4">4</a>]. Issues related to use of this regimen are discussed separately. (See  <a class="medical medical_review" href="/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">Rifapentine</a> inhibits DNA-dependent RNA polymerase in susceptible strains of <em>M. tuberculosis</em>. Rifapentine is bactericidal against both intracellular and extracellular <em>M. tuberculosis</em> organisms.</p><p class="headingAnchor" id="H14"><span class="h2">Resistance</span><span class="headingEndMark"> — </span>Strains of <em>M. tuberculosis</em> resistant to other rifamycins (including <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>) are likely to be resistant to <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a>, although drug susceptibility testing to rifapentine may be considered when rifampin resistance is observed and treatment options are limited.</p><p class="headingAnchor" id="H15"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">Rifapentine</a> absorption is increased in the presence of high-fat meals and divided doses [<a href="#rid58">58</a>]. Rifapentine has high protein binding (97 percent) [<a href="#rid59">59</a>]. The active metabolite is 25-desacetlyl rifapentine. Pharmacokinetic studies suggest that higher doses of the drug may be associated with higher concentrations of both free drug and metabolites [<a href="#rid60">60</a>]. Most of the drug is eliminated in the feces (approximately 70 percent).</p><p class="headingAnchor" id="H16"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>The dose of <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a> for adults and children &gt;12 years of age with tuberculosis is 10 to 20 mg/kg (600 mg) by mouth in a single dose given once weekly during the continuation phase of treatment (in combination with <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>) by directly observed therapy. </p><p>Investigations have examined the use of high-dose <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a> (1200 mg once daily with food) in combination with other antituberculosis drugs administered for four months for the treatment of pulmonary tuberculosis [<a href="#rid61">61</a>]. This regimen was noninferior to standard treatment and was generally well tolerated. However, the potential for increased rates of hyperbilirubinemia was noted in the rifapentine treatment arm, which requires close monitoring. </p><p>Limited data are available in children, but studies suggest the need for higher normalized weight-based dosing in order to achieve levels comparable with those in adults [<a href="#rid62">62</a>]. For the treatment of latent tuberculosis (in combination with <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>) in adults and children (≥2 years and ≥10 kg), a single oral dose of <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a> by mouth once weekly for 12 weeks (maximum of 900 mg/week) by directly observed therapy is administered based on weight as follows: ≥50 kg, 900 mg; 32.1 to 49.9 kg, 750 mg; 25.1 to 32 kg, 600 mg; 14.1 to 25 kg, 450 mg; and 10 to 14 kg, 300 mg [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H851613931"><span class="h2">Special populations</span><span class="headingEndMark"> — </span>Among pregnant women, clearance of <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a> in the setting of HIV infection is more rapid than among those without HIV infection [<a href="#rid63">63</a>]. </p><p class="headingAnchor" id="H18"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Adverse effects of <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a> include nausea/vomiting and hepatotoxicity. Hyperuricemia and elevations in liver function tests have been reported [<a href="#rid64">64</a>]. </p><p><a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">Rifapentine</a>, like other rifamycins, may produce an orange-red discoloration of body fluids (urine, tears, sputum, feces, and cerebrospinal fluid). Contact lenses and dentures can become permanently stained [<a href="#rid65">65</a>].</p><p>Severe adverse cutaneous reactions such as Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS) have been described [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p>When given once weekly with <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> for treatment of latent tuberculosis infection, reported reactions include a flu-like syndrome as well as more serious reactions including hypotension and syncope [<a href="#rid67">67</a>]. Questioning about side effects with a previous dose may prevent a more serious event; prodromal symptoms require holding the next dose until a clinical evaluation is performed.</p><p class="headingAnchor" id="H19"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Issues related to laboratory monitoring for patients on antituberculous drugs are discussed separately. (See  <a class="medical medical_review" href="/d/html/488.html" rel="external">"Antituberculous drugs: An overview", section on 'Clinical and laboratory monitoring'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">Rifapentine</a>, like other rifamycins, is a strong inducer of the cytochrome P450 (CYP) system. Use of rifapentine in patients on antiretroviral therapy is discussed further separately. (See  <a class="medical medical_review" href="/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection"</a>.)</p><p>Information regarding the interactions between <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a> (as a treatment for tuberculosis) and antiretrovirals is dynamic. The CDC maintains <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines%2Fhiv-clinical-guidelines-adult-and-adolescent-arv%2Foverview%3Fview%3Dfull&amp;token=lIaO8my2efZahcZ%2BWlFkcYfJsmvz9OI7OTXQbsNcmhXxWd1GcVR1MKig6y0KcROIQdfxE%2Bm1pHgw841say6yOGIq0GxLeS7miQ13OFlwpCCDbYym56j1MCbxtlee2sqB&amp;TOPIC_ID=491" target="_blank">guidelines</a> as to the management of such interactions [<a href="#rid55">55</a>].</p><p>Specific interactions of <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a> with other medications may be determined by using the <a class="external" href="/drug-interactions">drug interaction program</a> included within UpToDate. </p><p class="headingAnchor" id="H17082094"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The rifamycins include <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>, and <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a>. Of these, rifampin is most commonly used as first-line therapy (in combination with other agents) for treatment of mycobacterial infections including tuberculosis and in select invasive staphylococcal infections. The rate of development of resistance to rifamycins is high; for this reason, these agents are not used as monotherapy except for rifampin prophylaxis against <em>Neisseria meningitidis</em> or <em>Haemophilus influenzae</em>. (See <a class="local">'Introduction'</a> above and <a class="local">'Resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> undergoes rapid and complete absorption after oral administration. Absorption is improved when the drug is administered orally on an empty stomach. Rifampin undergoes wide distribution into most body tissues and fluids, including penetration into the cerebrospinal fluid. Intracellular concentrations (primarily in polymorphonuclear leukocytes) are up to five times higher than extracellular concentrations. (See <a class="local">'Pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> undergoes extensive hepatic metabolism to less active metabolites, with a half-life of three hours. Renal elimination of unchanged drug is minimal (&lt;30 percent); thus, no dose adjustments are required in patients with renal insufficiency. However, caution should be exercised when rifampin is administered to patients with significant hepatic disease, especially when used in combination with other hepatotoxins, such as <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>. (See <a class="local">'Pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cross-resistance of <em>Mycobacterium tuberculosis</em> isolates between rifamycins is not universal. Drug susceptibility testing to <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> or <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a> might be considered in the setting of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> resistance and limited treatment options.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adverse effects associated with the administration of rifamycins include gastrointestinal, central nervous system, and dermatologic and hematologic effects. Rifamycins may produce an orange-red discoloration of body fluids (urine, tears, sputum, feces, and spinal fluid). Hepatitis is infrequently associated with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> but is more commonly observed in patients with predisposing factors, including administration of concomitant hepatotoxins such as <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>. Uveitis, a rare complication in patients receiving <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>, is most likely a consequence of elevated rifabutin serum concentrations due to interacting drugs. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients receiving <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> as part of combination antituberculous therapy should undergo baseline evaluations of hepatic enzymes (aspartate aminotransferase, bilirubin, alkaline phosphatase), platelet count, and serum creatinine prior to the initiation of therapy. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients must be educated about possible symptoms of hepatic toxicity. Patients should be questioned regarding these symptoms at visits and should report any signs or symptoms that occur between visits. All patients should be fully evaluated clinically, including serum testing for hepatic injury. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug interactions result from the ability of rifamycins to induce the cytochrome P450 isoenzyme CYP3A4 (and to lesser extent CYP2C8 and CYP2C9) and uridine diphosphate gluconyltransferase 1A1 enzymes, potentially decreasing serum concentrations of coadministered drugs. In addition, serum concentrations of <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> (a substrate of CYP-3A4) may be altered by inducers or inhibitors of this enzyme. (See <a class="local">'Drug interactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">Rifabutin</a> is most commonly used in the treatment of mycobacterial infections in patients receiving concomitant medications exhibiting significant interactions with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (such as select antiretroviral therapies).</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010; 23:14.</a></li><li><a class="nounderline abstract_t">Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71:e1.</a></li><li><a class="nounderline abstract_t">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a class="nounderline abstract_t">Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Hajikhani B, Nasiri MJ, Adkinson BC, et al. Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment of Mycobacterium avium Complex: A meta-Analysis Study. Front Pharmacol 2021; 12:693369.</a></li><li><a class="nounderline abstract_t">Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 2001; 104:901.</a></li><li><a class="nounderline abstract_t">Boeree MJ, Diacon AH, Dawson R, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 2015; 191:1058.</a></li><li><a class="nounderline abstract_t">Yuen LK, Leslie D, Coloe PJ. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol 1999; 37:3844.</a></li><li><a class="nounderline abstract_t">Wichelhaus TA, Schäfer V, Brade V, Böddinghaus B. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:2813.</a></li><li><a class="nounderline abstract_t">Padayachee T, Klugman KP. Molecular basis of rifampin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43:2361.</a></li><li><a class="nounderline abstract_t">Drancourt M, Raoult D. Characterization of mutations in the rpoB gene in naturally rifampin-resistant Rickettsia species. Antimicrob Agents Chemother 1999; 43:2400.</a></li><li><a class="nounderline abstract_t">Huo F, Luo J, Shi J, et al. A 10-Year Comparative Analysis Shows that Increasing Prevalence of Rifampin-Resistant Mycobacterium tuberculosis in China Is Associated with the Transmission of Strains Harboring Compensatory Mutations. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Williams DL, Spring L, Collins L, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42:1853.</a></li><li><a class="nounderline abstract_t">Cavusoglu C, Karaca-Derici Y, Bilgic A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004; 10:662.</a></li><li><a class="nounderline abstract_t">Sirgel FA, Warren RM, Böttger EC, et al. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS One 2013; 8:e59414.</a></li><li class="breakAll">Zhang Y, Vilcheze C, Jacobs WR. Mechanisms of drug resistance in Mycobacterium tuberculosis. In: Tuberculosis and the tubercle bacillus, ASM Press, Washington, DC 2005. p.125.</li><li><a class="nounderline abstract_t">Farr B, Mandell GL. Rifampin. Med Clin North Am 1982; 66:157.</a></li><li><a class="nounderline abstract_t">Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. Antimicrob Agents Chemother 2016; 60:2171.</a></li><li><a class="nounderline abstract_t">Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999; 115:12.</a></li><li><a class="nounderline abstract_t">Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010; 16:1546.</a></li><li><a class="nounderline abstract_t">Jeremiah K, Denti P, Chigutsa E, et al. Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. Antimicrob Agents Chemother 2014; 58:3468.</a></li><li><a class="nounderline abstract_t">Stott KE, Pertinez H, Sturkenboom MGG, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother 2018; 73:2305.</a></li><li><a class="nounderline abstract_t">Wasserman S, Davis A, Stek C, et al. Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial. Antimicrob Agents Chemother 2021; 65:e0014021.</a></li><li><a class="nounderline abstract_t">Mandell GL, Vest TK. Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies. J Infect Dis 1972; 125:486.</a></li><li><a class="nounderline abstract_t">Chirehwa MT, Rustomjee R, Mthiyane T, et al. Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. Antimicrob Agents Chemother 2016; 60:487.</a></li><li><a class="nounderline abstract_t">Peloquin CA, Velásquez GE, Lecca L, et al. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Aarnoutse RE, Kibiki GS, Reither K, et al. Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Cresswell FV, Meya DB, Kagimu E, et al. High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clin Infect Dis 2021; 73:876.</a></li><li><a class="nounderline abstract_t">Onorato L, Gentile V, Russo A, et al. Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis. Clin Microbiol Infect 2021; 27:830.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Treatment for TB During Pregnancy. https://www.cdc.gov/tb/topic/treatment/pregnancy.htm (Accessed on August 15, 2022).</li><li><a class="nounderline abstract_t">Martínez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) 1999; 78:361.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC), American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:735.</a></li><li><a class="nounderline abstract_t">Dhhar G, McColl J, Kitai I, et al. Rifampin-induced flu-like syndrome with shock in a patient with tuberculosis infection. CMAJ 2023; 195:E1151.</a></li><li><a class="nounderline abstract_t">Vesely JJ, Pien FD, Pien BC. Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy 1998; 18:345.</a></li><li><a class="nounderline abstract_t">Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992; 22:47.</a></li><li><a class="nounderline abstract_t">Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008; 335:126.</a></li><li><a class="nounderline abstract_t">Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin 2013; 29:1.</a></li><li class="breakAll">Sanofi. Rifadin. https://products.sanofi.us/rifadin/rifadin.pdf (Accessed on December 17, 2021).</li><li><a class="nounderline abstract_t">Panomvana Na Ayudhya D, Thanompuangseree N, Tansuphaswadikul S. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin Pharmacokinet 2004; 43:725.</a></li><li><a class="nounderline abstract_t">Ndanusa BU, Mustapha A, Abdu-Aguye I. The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. J Pharm Biomed Anal 1997; 15:1571.</a></li><li><a class="nounderline abstract_t">Kyrklund C, Backman JT, Kivistö KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68:592.</a></li><li><a class="nounderline abstract_t">Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet 2003; 42:819.</a></li><li><a class="nounderline abstract_t">Tuloup V, France M, Garreau R, et al. Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. Antimicrob Agents Chemother 2021; 65:e0104321.</a></li><li class="breakAll">AIDS info. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (Accessed on December 08, 2014).</li><li class="breakAll">Mycobutin [package insert]. New York, NY: Pharmacia &amp; Upjohn Company; 2007.</li><li><a class="nounderline abstract_t">Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112:212.</a></li><li><a class="nounderline abstract_t">Trebosc V, Schellhorn B, Schill J, et al. In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms. J Antimicrob Chemother 2020; 75:3552.</a></li><li><a class="nounderline abstract_t">Berrada ZL, Lin SY, Rodwell TC, et al. Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn Microbiol Infect Dis 2016; 85:177.</a></li><li class="breakAll">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf (Accessed on April 12, 2022).</li><li class="breakAll">Clinicalinfo.hiv.gov. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/drug-interactions-between-protease-inhibitors-and-other-drugs (Accessed on December 17, 2021).</li><li><a class="nounderline abstract_t">Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996; 22 Suppl 1:S15.</a></li><li><a class="nounderline abstract_t">Bassilios N, Launay-Vacher V, Hamani AA, et al. Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient. Nephrol Dial Transplant 2002; 17:531.</a></li><li><a class="nounderline abstract_t">Tseng AL, Walmsley SL. Rifabutin-associated uveitis. Ann Pharmacother 1995; 29:1149.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. https://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/default.htm (Accessed on December 08, 2014).</li><li><a class="nounderline abstract_t">Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet 2011; 50:25.</a></li><li><a class="nounderline abstract_t">Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis 2012; 206:1030.</a></li><li><a class="nounderline abstract_t">Dooley KE, Savic RM, Park JG, et al. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother 2015; 59:3399.</a></li><li><a class="nounderline abstract_t">Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40:327.</a></li><li><a class="nounderline abstract_t">CONWAY N, BIRT BD. STREPTOMYCIN IN PREGNANCY: EFFECT ON THE FOETAL EAR. Br Med J 1965; 2:260.</a></li><li><a class="nounderline abstract_t">Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021; 384:1705.</a></li><li><a class="nounderline abstract_t">Blake MJ, Abdel-Rahman SM, Jacobs RF, et al. Pharmacokinetics of rifapentine in children. Pediatr Infect Dis J 2006; 25:405.</a></li><li><a class="nounderline abstract_t">Mathad JS, Savic R, Britto P, et al. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. Clin Infect Dis 2022; 74:1604.</a></li><li><a class="nounderline abstract_t">Jarvis B, Lamb HM. Rifapentine. Drugs 1998; 56:607.</a></li><li><a class="nounderline abstract_t">Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis 2006; 43:1468.</a></li><li class="breakAll">US Food and Drug Administration. PRIFTIN®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021024s017s018lbl.pdf (Accessed on June 09, 2020).</li><li><a class="nounderline abstract_t">Sterling TR, Moro RN, Borisov AS, et al. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis 2015; 61:527.</a></li></ol></div><div id="topicVersionRevision">Topic 491 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20065324" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rifampin combination therapy for nonmycobacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32628747" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32053584" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34557091" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment of Mycobacterium avium Complex: A meta-Analysis Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11290327" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Structural mechanism for rifampicin inhibition of bacterial rna polymerase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25654354" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10565894" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10543773" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10508007" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Molecular basis of rifampin resistance in Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10508014" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Characterization of mutations in the rpoB gene in naturally rifampin-resistant Rickettsia species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29378712" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A 10-Year Comparative Analysis Shows that Increasing Prevalence of Rifampin-Resistant Mycobacterium tuberculosis in China Is Associated with the Transmission of Strains Harboring Compensatory Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661035" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15214882" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23527189" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23527189" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7038325" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26810651" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9925057" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20875279" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24709267" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29701775" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33972248" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5023643" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26552972" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28559269" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28827417" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33693537" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33813119" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10575418" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12904741" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37669793" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Rifampin-induced flu-like syndrome with shock in a patient with tuberculosis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9545154" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Rifampin, a useful drug for nonmycobacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1559307" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pharmacokinetic drug interactions with rifampicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18277121" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Update on rifampin and rifabutin drug interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23136913" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Update on rifampin, rifabutin, and rifapentine drug interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23136913" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Update on rifampin, rifabutin, and rifapentine drug interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15301576" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9226591" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11180018" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12882588" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pharmacokinetic interactions with rifampicin : clinical relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34228545" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34228545" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34228545" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28071659" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32869081" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27036978" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27036978" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27036978" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8785251" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The clinical pharmacokinetics of rifabutin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11865118" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8573961" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Rifabutin-associated uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8573961" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rifabutin-associated uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21142266" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22850121" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25824215" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11432536" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14310200" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : STREPTOMYCIN IN PREGNANCY: EFFECT ON THE FOETAL EAR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33951360" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645503" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pharmacokinetics of rifapentine in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34323955" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9806107" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Rifapentine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17083024" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Rifapentine for the treatment of pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17083024" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Rifapentine for the treatment of pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25904367" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
